Inactive SARS-COV-2 Vaccine Adverse Effects Among Hospital Workers

Year 2021, Volume: 7 Issue: 14, 42 - 45, 31.10.2021

Esen Sayın Gülensoy , Aycan Yüksel , Nalan Ogan , Aslıhan Alhan , Evrim Akpınar

https://doi.org/10.48121/jihsam.950805

Abstract

Covid-19 is a contagious viral infection with serious complications. Since a proven treatment for such a disease with high mortality has not yet been found, vaccination studies are important for preventative measures and rapid herd immunity. In a period when the whole world urgently needs vaccines, objective scientific data on about the safety of the vaccine are necessary. After the Sars-Cov-2 vaccine (CoronaVac) first and second dose was administered to the employees of Ufuk University Faculty of Medicine, the adverse effects they encountered in the early period were requested. 173 participants completed the survey. When systemic and local adverse effects seen in the first week after vaccination are reported, most of the adverse effects observed were mild adverse effects. Anaphylaxis with dyspnea and syncope developed on only one participant after vaccination. No serious adverse effects of the Sars-Cov-2 vaccine, whose Phase I / II studies have been published, have been reported. In our study where we evaluated early adverse effects with a limited number of participants, we did not find any serious adverse effects in healthcare workers. Anaphylaxis with dyspnea and syncope was observed in one participant that recovered. There is an ongoing need for studies on effect, adverse effects, and efficacy of the Inactive Sars-Cov-2 vaccine as Phase III results have not been published yet.

Keywords

Covid-19, inactive vaccine, adverse effect, vaccination

References

• Referans1 Callaway E,(2020) The race for coronavirus vaccines: a graphical guide, Nature, Vol 580, 30 April 2020
• Referans2 COVID-19 (SARS-CoV-2 Enfeksiyonu) T.C. Sağlık bakanlığı Rehberi Genel Bilgiler, Epidemiyoloji ve Tanı, https://covid19.saglik.gov.tr/TR-66337/genel-bilgiler-epidemiyoloji-ve-tani.html
• Referans3 Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VC et al. (2020) Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. Emerg Infect Dis. 26:1478–88.
• Referans4 Poland GA, Ovsyannikova IG, Kennedy RB. (2020) SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates Lancet 396: 1595–606.
• Referans5 Remy V, Largeron, N, Quilici, S, Carroll, S, The economic value of vaccination: why prevention is wealth, Value in Health, 2015, 17, 450.
• Referans6 Wu Z, McGoogan JM. (2020) Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 24;323(13):1239–42.
• Referans7 Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jianget Z et al. (2021) Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial. Lancet Infect Dis, 3. DOI: 10.1016/ S1473- 3099(20)30987-7
• Referans8 Varghese PM,Tsolaki AG, Yasmin H, Shastri A, Ferluga J, Vatish M et al. (2020) Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. Immunobiology, 225:152008.
• Referans9 Yanjun Zhang, Gang Zeng, Hongxing Pan, Changgui Li, Yaling Hu, Kai Chu, et al., (2021) safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial, Lancet Infect Dis; 21: 181–92